Evaluation of Reversed Administration Order of Busulfan (BU) and Cyclophosphamide (CY) as Conditioning on Liver Toxicity in Allogenic Hematopoietic Stem Cell Transplantation (ALL-HSCT)

Mani Ramzi¹, Nasrin Namdari², Shirin Haghghat³, Hourvash Haghbinejad⁴

¹Hematology and Bone Marrow Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
²Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
³Department of Hematology, Hematology Research Center, Medical Oncology and Stem Cell Transplantation, Shiraz University of Medical Sciences, Shiraz, Iran
⁴Department of Family Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Corresponding Author: Mani Ramzi, Hematology and Bone Marrow Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Email: ramzim@sums.ac.ir

ABSTRACT

Background: Busulfan (BU) in combination with cyclophosphamide (CY) is used as an effective conditioning regimen in hematopoietic SCT. Busulfan, depletes glutathione level in liver and causes elevated levels of CY metabolites. Cyclophosphamide metabolites are highly toxic for sinusoidal endothelial cells and cause VOD/SOS with high mortality rate.

Materials and Methods: All adult patients with acute leukemia, who were candidates for myeloablative allogenic SCT admitted in Stem Cell Transplantation center of our center were enrolled in this prospective randomized clinical trial during 2 years. We tested the hypothesis that reverse administration from BU-CY (28 patients) to CY-BU group (27 patients) would reduce liver toxicity.

Results: Liver function tests were significantly higher in BU-CY group between day -1 and +4 (p<0.05), but we do not have VOD/SOS in both groups. The incidence and severity of acute GVHD was higher in BU-CY group, but not statistically significant. Engraftment and mortality rate were not different.

Conclusion: These data support the concept that CY-BU is associated with less liver toxicity, suggesting CY-BU is superior to BU-CY as conditioning.

Keywords: Allogeneic transplant; Conditioning; Busulfan; Cyclophosphamide

INTRODUCTION

Hematopoietic Stem cell Transplantation is a curative therapy for a number of malignant and non-malignant disorders. Busulfan followed by Cyclophosphamide (BU-CY) is used as an effective conditioning regimen in allogeneic hematopoietic Cell Transplantation. Liver toxicity and hepatic sinusoidal obstruction syndrome (SOS), also known as Hepatic Veno-occlusive disease (VOD) is a potentially life-threatening complication that can occur after myeloablative hematopoietic stem cell transplantation. Incidence of VOD/SOS ranges from 8-14%, and its severe form is associated with mortality rate higher than 80%. VOD/SOS begins with injury to sinusoidal endothelial cells and hepatocytes due to toxic metabolites generated by high dose alkylating chemotherapy conditioning regimens, such as busulfan,
cyclophosphamide, melphalan, 6-mercaptopurine and possibly Thiotepa.7 Busulfan and Cyclophosphamide are metabolized in liver8,9. Busulfan is not toxic for hepatocytes and sinusoidal endothelial cells, but metabolites of cyclophosphamide are highly toxic to sinusoidal endothelial cells10-12. Cytotoxic effect of cyclophosphamide is mediated by its active metabolites such as 4-hydroxy cyclophosphamide(4-OHCP) and phosphoramidemustard(PM). The extent of cyclophosphamide metabolism depends, in part, on the activity and concentration of aldehyde dehydrogenase, glutathione and glutathione S-Transferase13-15. Glutathione is involved in busulfan clearance, and starting conditioning regimens with busulfan, depletes glutathione level in liver and causes elevated levels of cyclophosphamide metabolites11-12,17. Restoration of hepatic and sinusoidal endothelial cell glutathione levels prevents injury to hepatic sinusoidalain several different animal models of toxic liver injury18. Cyclophosphamide administration in less than 24 hours after the last dose of busulfan, causes more mucositis and VOD/SOS because of negative effect on cyclophosphamide pharmacokinetics19. Studies have suggested less hepatotoxicity when busulfan is administered after cyclophosphamide8,19-21.

Here, we report a prospective randomized clinical trial designed to test the hypothesis that reverse administration of CY and BU reduces hepatotoxicity in comparison to standard BU-CY conditioning regimen.

MATERIALS AND METHODS

All adult patients with acute leukemia, who were candidate for myeloablative allogenic SCT admitted in Stem Cell Transplantation center of Shiraz were enrolled in this prospective randomized clinical trial during 2 years. They referred to our hospital from September 2013 to September 2015. All eligible patients were provided written informed consent. All procedures were in accordance with the Helsinki protocol of 1975 and approved by Ethics Committee of Shiraz University of Medical Sciences (Shiraz, Iran)

Inclusion criteria:

- Eligibility criteria included: 1) patients with acute leukemia (ALL and AML) that needs Allogenic SCT2) age ≥15 years 3) Karnofski performance status of >70% at the time of HCT
- Exclusion criteria: 1) HIV infection 2) chronic liver disease 3) active hepatitis
- Conditioning regimen:
  - Patients randomized to two groups: CY-BU and BU-CY.
  - Patients in CY-BU group(n=27) received cyclophosphamide on days -8 through -6, and busulfan on days -5 through -2. Transplantation was done on day 0. Patients in control group (BU-CY, n=28) received busulfan on days -8 through -5 and cyclophosphamide on days -4 through -2.
  - Cyclophosphamide was administered with total dose of 120 mg/kg i.v and busulfan i.v with dose of 0.8 mg/kg/dose every 6 hours, for a total 16 doses.
  - Prophylactic phenytoin was given from days -8 through -2 to all patients. Graft-versus-Host-disease prophylaxis consisted of cyclosporine and metothrexate. Cyclosporin was given from day -1 as an i.v route with 3mg/kg/d, with adjusted doses according to cyclosporine level. Cyclosporin was changed to oral route when the patients could tolerate oral dose. Metothrexate was given at a dose of 10 mg/m² i.v on days +1, +3, +6 and +11. All patients received antifungal, antiviral, antibacterial and ursodiol prophylaxis in accordance to standard practice.
  - We checked liver function tests on admission, before starting conditioning regimen, one day before transplantation, on transplantation day and on days +4, +8, +12, +16, +20 and +30. The patients were followed till days +100 for GVHD presentation and mortality. Neutrophil engraftment was defined first day of two consecutive days of PMN ≥500/dl.

Statistical analyses

Statistical comparisons of engraftment between two groups was done by independent t test. Frequency of GVHD was compared by chi square test between two groups. Comparison of the liver function tests between two groups was done using Mann-whitney test.
RESULTS
Patients and their characteristics are summarized in Table 1. The median age of patients in BU-CY group was 30 years (range, 15-61 years). Sixteen patients (57.1%) were male and 12 (42.9%) were female. Thirteen patients (46.43%) had ALL, 13 (46.43%) had AML and 2 (7.14%) had MDS. The median age of patients in CY-BU group was 31 years (range: 20-53 years). Seventeen patients (63%) were male and ten (37%) were female. Nine (33.3%) had ALL, 18 (66.7%) had AML and none of them had MDS.
There was no statistically significant difference between two groups according to age, sex and underlying disease distribution. All transplants were from HLA-matched sibling donors, except one of them, was HLA-matched from his child.

Engraftment
Median times to myeloid engraftment (BU-CY cohort 13 days (range: 9-17) vs CY-BU cohort 13 days (range: 10-18)) were similar between two groups (P-value: 0.93).

Graft Versus Host Disease
The cumulative incidence of acute GVHD at day +100 was 46.6% in the BU-CY group and 37% in CY-BU group (p-value= 0.48). Severity of acute GVHD in BU-CY group was 30.8% grade 1, 38.5% grade 2, 7.7% grade 3, and 23.1% grade 4. None of the patients in CY-BU group had grade 1 and 4 GVHD, 90% had grade 2 and 10% grade 3.
Skin was the most frequent involved organ between two groups. GVHD was more severe in BU-CY group (38.4% grade 3 and 4) compared with CY-BU group (10% grade 3 and 4).

Liver toxicity
Diagnosis of VOD/SOS was not made in both groups. Liver function tests including Alkaline phosphatase and bilirubin were not statistically significant different between two groups, but mean values of ALT on one day before (p=0.02), transplantation day (p=0.025) and day +4 post-transplant (p=0.03) were significantly higher in control group (figure 1).
Mean values of AST on one day before (p=0.001) and transplantation day (p=0.001) were significantly higher in control group (Figure 1).

Table1. Patients Characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>BU-CY</th>
<th>CY-BU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Patients, n%</td>
<td>28</td>
<td>27</td>
</tr>
<tr>
<td>Sex, n%</td>
<td></td>
<td>0.66</td>
</tr>
<tr>
<td>Male</td>
<td>16(57.1%)</td>
<td>17(63%)</td>
</tr>
<tr>
<td>Female</td>
<td>12(42.9%)</td>
<td>10(37%)</td>
</tr>
<tr>
<td>Age, median (range)</td>
<td></td>
<td>0.82</td>
</tr>
<tr>
<td>All</td>
<td>12(44.4%)</td>
<td>9(33.3%)</td>
</tr>
<tr>
<td>AML</td>
<td>13(48.1%)</td>
<td>18(66.7%)</td>
</tr>
<tr>
<td>MDS</td>
<td>2(7.4%)</td>
<td>0(0%)</td>
</tr>
<tr>
<td>Donor, n%</td>
<td>0.36</td>
<td></td>
</tr>
<tr>
<td>Identical Sibling</td>
<td>26(96.3%)</td>
<td>27(100%)</td>
</tr>
<tr>
<td>Other family members</td>
<td>1(3.7%)</td>
<td>0(0%)</td>
</tr>
<tr>
<td>Disease condition at Transplantation</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>First remission</td>
<td>15(55.6%)</td>
<td>20(74.1%)</td>
</tr>
<tr>
<td>Second remission</td>
<td>3(11.1%)</td>
<td>3(11.1%)</td>
</tr>
<tr>
<td>Others</td>
<td>9(14.8%)</td>
<td>4(14.8%)</td>
</tr>
</tbody>
</table>

Mortality
The cumulative incidence of TRM at day +100 was 10.7% in BU-CY group and 3.7% in CY-BU group (p=0.32). Causes of TRM in the BU-CY group was relapse (1 patient, 3.57%), GVHD (1 patient, 3.57%) and GVHD simultaneous with CMV infection (1 patient, 3.57%), and those in CY-BU group was GVHD (1 patient, 3.7%).
Figure 1. Mean serum levels of AST, ALT, T. bilirubin, D.bilirubin and Alkaline phosphatase for the BU-CY and CY-Bu group at day -8 (before starting the conditioning regimen), -1 (one day before transplantation), 0, +4, +8, +12, +16, +20 and +30.

DISCUSSION

One of the possible approaches to minimizing liver toxicity caused by BU-Cy conditioning is reversing the order of administration, giving CY followed by busulfan. Median time to myeloid engraftment was not different between BU-CY and CY-BU group in our study (p = 0.93). Our results were comparable with those of Cantoni et al. and Kerbauy et al. Myeloid engraftment was similar in mice treated with BU-CY v/s CY-BU conditioning regimen.\textsuperscript{8,20} It seems that reverse administration of conditioning regimen does not affect myeloid engraftment.

The incidence of acute GVHD were similar between two groups (46.4% in BU-CY and 37% in CY-BU, p=0.48) in our study, but patients in BU-CY group had more severe GVHD (grade 3 and 4) relative to CY-BU group(38.4% vs 10%). Cantoni et al. demonstrated that patients in BU-CY group had more acute GVHD relative to patients in CY-BU group(75% vs 44%, p=0.001), but severity of acute GVHD were similar between two groups\textsuperscript{8}.

Liver toxicity and VOD/SOS is a potentially life-threatening complication after myeloablative hematopoietic stem cell transplantation. In our study, mean values of AST and ALT were significantly higher in BU-CY group in comparison to CY-BU group (p<0.05). In the study by Cantoni et al. the incidence of SOS was significantly higher in BU-CY group patients (12.5% vs 0% in CY-BU group) (p= 0.006). also, serum levels of liver function tests were higher in patients with BU-CY conditioning regimen.\textsuperscript{8}
study by Kerbauy et al. liver function tests were significantly higher in patients with BU-CY group (p<0.05) and similar results has been reported20. Rezvani et al. evaluated administering Cyclophosphamide followed by intravenous targeted busulfan in patients with AML, MDS and myelofibrosis. Compared with BU-CY conditioned patients, CY-BU conditioned patients had greater exposure to cyclophosphamide and less exposure to hydroxycyclophosphamide21.

In patients with myelofibrosis, incidence of SOS was significantly lower in patients with CY-BU cohort in comparison to BU-CY (0% vs 30%), whereas the incidence of SOS was low in both cohorts with AML and MDS. Rezvani et al. recommends CY-BU as a superior conditioning regimen in patients with myelofibrosis21.

CONCLUSION
According to our results and other studies, it seems that CY-BU conditioning is associated with less liver toxicity, VOD/SOS and acute GVHD without interfering with engraftment and mortality rate. Our finding in good concordance of previous studies showed that CY-BU is effective and less toxic and transplant centers can use it as replacement choice of conditioning regime.

ACKNOWLEDGMENT
The authors thank the vice-chancellery of Shiraz University of medical sciences for supporting this research. This article is based on a theses performed by Dr. Nasrin Namdari.

REFERENCES

Reversed administration of BU and CY on Liver Toxicity in ALL-HSCT


